Development of a novel clinical biomarker assay to detect and quantify aggrecanase-generated aggrecan fragments in human synovial fluid, serum and urine  by Swearingen, C.A. et al.
Osteoarthritis and Cartilage 18 (2010) 1150e1158Development of a novel clinical biomarker assay to detect and quantify
aggrecanase-generated aggrecan fragments in human synovial ﬂuid,
serum and urine
C.A. Swearingen ya, J.W. Carpenter za, R. Siegel z, I.J. Brittain z, J. Dotzlaf z, T.B. Durham x, J.L. Toth x,
D.A. Laska z, J. Marimuthu x, C. Liu x, D.P. Brown z, Q.L. Carter z, M.R. Wiley x, K.L. Dufﬁn z,
P.G. Mitchell y, K. Thirunavukkarasu y*
yMusculoskeletal Research, Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN 46285, USA
z Integrative Biology, Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN 46285, USA
xDiscovery Chemistry, Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN 46285, USAa r t i c l e i n f o
Article history:
Received 7 November 2009
Accepted 10 June 2010
Keywords:
Aggrecanase
Aggrecan
Neoepitope antibody
ARGS
Hyaluronic-acid binding region (HABR)
Biomarker
Sandwich ELISA* Address correspondence and reprint requests to:
E-mail address: kannan@lilly.com (K. Thirunavukk
a These authors contributed equally to this work.
1063-4584/$ e see front matter  2010 Osteoarthriti
doi:10.1016/j.joca.2010.06.011s u m m a r y
Objective: Proteolytic degradation of aggrecan in articular cartilage is a hallmark feature of osteoarthritis
(OA). The present study was aimed at developing a sensitive enzyme linked immunosorbent assay
(ELISA) for the detection of aggrecanase-cleaved fragments of aggrecan in human serum and urine to
facilitate the clinical development of aggrecanase inhibitors for OA.
Methods: The BC3monoclonal antibody that detects the ARGS neoepitope sequence in aggrecanase-cleaved
aggrecan was engineered and optimized using complementarity determining region (CDR)-saturation
mutagenesis to improve its binding afﬁnity to the neoepitope. A sandwich ELISA (BC3-C2 ELISA) was
developed using the optimized a-ARGS antibody (BC3-C2) as capture antibody and a commercially available
antibody directed against the hyaluronic-acid binding region (HABR) of aggrecan as detection antibody.
Aggrecanase-cleaved fragments of aggrecan present in in vitro digests, human cartilage explant culture
supernatants and in human synovial ﬂuid, serum and urine were detected and quantiﬁed using this ELISA.
Results: The optimized antibody had a 4-log improvement in afﬁnity for the ARGS containing peptide
compared to the parental BC3 antibody, while maintaining the ability to not cross-react with a spanning
peptide. The BC3-C2 ELISA demonstrated the ability to detect aggrecanase-cleaved aggrecan fragments in
the native state, without the need for deglycosylation. This ELISA was able to measure aggrecanase-
generated ARGS containing aggrecan fragments in human articular cartilage (HAC) explant cultures in
the basal state (without cytokine stimulation). Treatment with an aggrecanase inhibitor resulted in
a dose-dependent inhibition of ARGS neoepitope released into the culture supernatant. The ELISA assay
also enabled the detection of ARGS containing fragments in human synovial ﬂuid, serum and urine,
suggesting its potential utility as a biomarker of aggrecanase activity.
Conclusions: We have developed a novel ELISA using an optimized ARGS antibody and have demon-
strated for the ﬁrst time, an ELISA-based measurement of aggrecan degradation products in human
serum and urine. This assay has the potential to serve as a mechanistic drug activity biomarker in the
clinic and is expected to signiﬁcantly impact/accelerate the clinical development of aggrecanase inhib-
itors and other disease modifying drugs for OA.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
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family cleave aggrecan in vitro, ADAMTS-4 (aggrecanase-1) and
ADAMTS-5 (aggrecanase-2) show the highest speciﬁc activity for
cleaving aggrecan1. In vitro studies using small molecule inhibitors
of aggrecanase activity and in vivo studies using knockout mice
have shed light on the importance of these proteases in cartilage
matrix turnover in normal physiology and in cartilage degradation
in pathological states2e5. In a surgical model of OA, ADAMTS-4
knockout animals are not protected from cartilage degradation2
whereas ADAMTS-5 knockout mice3,5 and ADAMTS-4 and -5
double knockout mice6 are signiﬁcantly protected from cartilage
damage, implicating ADAMTS-5 to be the critical enzyme involved
in pathological aggrecan degradation in mice. In addition,
comparative studies on the proteolytic activities of ADAMTS-4 and
ADAMTS-5 indicate that ADAMTS-5 is about 30-fold more active
than ADAMTS-4 in cleaving aggrecan in vitro7. However, inhibition
of aggrecanase activity in human cartilage explant cultures using
small molecule inhibitors4 or siRNA knockdown8 suggests the
involvement of both ADAMTS-4 and ADAMTS-5 in aggrecan
degradation. Identiﬁcation of selective inhibitors of these two
enzymes would help to determine their relative contribution to
physiological/pathological aggrecan degradation in humans.
Aggrecanases have been shown to cleave aggrecan at ﬁve loca-
tions in the core protein, four in the chondroitin sulfate (CS)-rich
C-terminus of the protein and one at a site within the interglobular
domain (IGD)9,10. Cleavage of aggrecanwithin the IGD occurs within
the E373eA374 bond that results in the generation of NITEGE373 and
374ARGS neoepitope sequences11. Release of the ARGS containing
fragments is likely to disrupt the mechanical integrity of cartilage,
as it results in the loss of the keratan sulfate (KS) and CS-rich
C-terminus of aggrecan that plays a major role in maintaining the
functionality of aggrecan (water-holding capacity, compressibility
and elasticity). Mutation of the aggrecanase cleavage site within the
IGD in mice makes the animals resistant to aggrecan loss and carti-
lage erosion in surgical and inﬂammatory models of OA12, thereby
implicating the importance of this cleavage in cartilage destruction
in thesemousemodels. Aggrecanase-cleaved fragments of aggrecan
are found in synovial ﬂuid from patients with OA, joint injury and
inﬂammatory joint disease13,14, suggestive of the involvement of
aggrecanases in the pathogenesis of these joint disorders in humans.
Detection and quantiﬁcation of these fragments in human biological
ﬂuids (synovial ﬂuid, serum and/or urine) could serve as biomarkers
of disease status of the joint and could facilitate the identiﬁcation
and clinical development of aggrecanase inhibitors that have the
potential to inhibit cartilage damage.
The assays available today to measure proteoglycan levels in
human biological ﬂuids either lack speciﬁcity for detecting aggre-
canase-cleaved fragments (e.g., DMMB dye-binding assay and 1-
F21 competition enzyme linked immunosorbent assay (ELISA))15,16
or, are limited by their ability to detect aggrecanase-generated
aggrecan fragments only in human synovial ﬂuid samples14,17 that
have a relative abundance of these fragments compared to the
peripheral levels in systemic circulation or in urine15. Quantiﬁca-
tion of speciﬁc aggrecanase-cleaved aggrecan fragments is
considered to be a more reliable marker of disease activity in the
joint compared to the quantiﬁcation of general proteoglycan levels
or other proteolytic fragments of aggrecan14. The sandwich ELISA
described by Pratta et al.17 makes use of an a-KS antibody and an a-
ARGS antibody18 to detect aggrecanase-cleaved aggrecan frag-
ments in human synovial ﬂuid samples. However, this assay is not
capable of measuring ARGS containing fragments in serum or urine,
likely due to the lower levels of this epitope in serum and urine.
The recent advent of in vitro display technologies19e21 provides
the ﬂexibility to engineer new attributes or augment speciﬁc attri-
butes of interest (such as afﬁnity, speciﬁcity or stability) intopreviously isolated antibody molecules, a process often termed
“directedevolution”. In aneffort todevelopaclinicalbiomarkerassay
for measuring ARGS containing aggrecan fragments in clinically
accessible humanﬂuids (serumandurine),we sought to improve the
afﬁnity of the BC3 antibody and succeeded in identifying an opti-
mized antibody (BC3-C2) that had a 10,000-fold improvement in
afﬁnity for theARGS peptide compared to the parental BC3 antibody.
Using the BC3-C2 antibody, we have developed a sensitive sandwich
ELISA that is capable of measuring ARGS fragments in human syno-
vial ﬂuid, serum and urine in the native state, without the need for
deglycosylation. To our knowledge, this is the ﬁrst evidence for an
ELISA-based biomarker assay that can speciﬁcally measure aggre-
canase-cleaved aggrecan fragments in human systemic circulation
and in urine. This assay has the potential to serve as a mechanistic
drug activity biomarkerassay to facilitate the clinical developmentof
aggrecanase inhibitors and other disease modifying drugs for OA.
Materials and methods
Aggrecanase and aggrecan
Truncated human recombinant aggrecanase-1/ADAMTS-4 (213-
579) with a C-terminal oligohistidine tag was expressed in HEK 293
cells. Puriﬁed human aggrecan was obtained from Dr. John Sandy
(Rush University, Chicago).
Human clinical samples
Human articular cartilage (HAC) (Clarion Tissue Bank, Indian-
apolis, IN) and synovial ﬂuid (St. Francis Hospital, Beech Grove, IN)
were obtained from the knee joints of patients undergoing knee
replacement surgery, under a protocol approved by the institu-
tional review boards (IRBs), with informed consent from the
patients. The synovial ﬂuid samples were treated with hyaluroni-
dase to reduce sample viscosity prior to testing them in the ELISA.
Human serum and urine were obtained with informed consent
from individuals enrolled in a methods study conducted by Lilly,
under an IRB approved protocol. The individuals in the methods
study were identiﬁed as having no, mild or moderate OA (n¼ 14/
group)basedonclinical examsandradiographic analysis of theknee,
hip and spine. Serum and urine samples were collected at baseline
(visit 1) and at 2-week (visit 2) and 4-week (visit 3) follow-up.
Antibodies and competitor peptides
The monoclonal a-hyaluronic-acid binding region (HABR) anti-
body (that binds to both the G1 and G2 domains of aggrecan) was
purchased from Invitrogen (catalog # AHP0022; clone number
969D4D11). The monoclonal antibody BC3 that recognizes the
ARGS neoepitope sequence18 was obtained from Novus Biologicals
and was puriﬁed on a Protein G column. The BC3-C2 antibody was
developed at Lilly as detailed below. The 22-mer competing peptide
(ARGSVILTVKPIFEVSPSPLKG) and the 43-mer spanning peptide
(VQTVTWPDMELPLPRNITEGEARGSVILTVKPIFEVSPSPLKG) were
obtained from Midwest Biotech, Fishers, IN. The biotinylated
antigen (ARGS-Bt ARGSVILTVKPIFEVSPSK-Bt) and ARGN-Bt
(ARGSVILTAKPIFDMSPTK-Bt) and the spanning competitor peptide
(GGNITEGEARGSVIC) used for afﬁnity maturation were obtained
from CPC Scientiﬁc (San Jose, CA).
Afﬁnity maturation of the BC3 antibody
The BC3-producing hybridoma was obtained from Dr. Bruce
Caterson18 and was optimized using yeast cell surface display, as
previously described22, with exceptions. Brieﬂy, mRNA was
C.A. Swearingen et al. / Osteoarthritis and Cartilage 18 (2010) 1150e11581152extracted, the BC3 VH and VL genes were ampliﬁed from cDNA
using Mouse Ig Primer set (Novagen, San Diego, CA) and sequences
determined after insertion into TA TOPO cloning vector (Invi-
trogen). The BC3 WT scFv gene, in which the antigen-speciﬁc VH
and VL domains are linked into a single polypeptide, was created by
single overlap extension PCR (SOE-PCR) and ligated into pYD6 yeast
display vector [derived from pYD1 vector (Invitrogen)] after
digestion with Sﬁ1 restriction enzyme.
Spiked mutagenesis with degenerate oligonucleotides was
used for saturation mutagenesis of the VH and VL comple-
mentarity determining regions (CDRs). Individual CDR libraries
were constructed by recombining the mutated scFv DNA pool
into pYD6 vector digested with Sﬁ1 after co-transformation
into EBY100 yeast (Invitrogen) using lithium acetate as
described23,24 and propagated in SD-CAA media at 30C with
shaking.
scFv expression was induced by transferring mid-log growth
cells into SG-CAA (2% galactose replaces 2% glucose) media and
grown at 20C for 12e24 h with shaking. An overrepresentation
(>10) of each CDR library or sort output from a previous round of
selection was incubated with ARGS-Bt peptide and a-V5 mAb
(1 mg/L) (Invitrogen) in selection buffer (PBS pH 7.4, 0.5% BSA) at
25C for 30 min prior to transfer to ice and washing with cold
selection buffer. Bound antigen was detected using streptavidin-R-
phycoerythrin (SAePE) (1:200 dilution) and binding was normal-
ized to the amount of scFv expression using Alexa Fluor 488 goat
a-mouse (GaM-488) (1:100 dilution) (Invitrogen). Clones of
interest were enriched using ﬂuorescence-assisted cell sorting on
a FACSAria cell sorter (BD Biosciences). Three rounds of selection
were performed per library and an aliquot of cells after each round
of selection was plated on CM glucose e Trp-Ura-His agar plates
(Technova).
Individual clones from CDR libraries with improved binding
from the third round of selection were sequenced. Individual
mutations from VH and VL CDR regions were combined by SOE-PCR
to construct combinatorial mutant BC3-C2 and the relative binding
afﬁnity determined after ARGS-Bt and ARGN-Bt antigen titra-
tion25,26. The resulting VH and VL genes were ligated into separate
human IgG or IgK expression vectors, respectively, and BC3-C2
chimeric murine/human IgG4 puriﬁed by protein A after large scale
transient transfection using HEK 293 cells.Biacore analysis
Kinetic analysis and binding speciﬁcity of BC3 and BC3-C2
were determined using a Biacore T100 instrument. A Series S
Sensor Chip CM5 (Biacore, BR-1006-68) was preconditioned and
w6000 response units of goat a-mouse k capture antibody (1050-
01, Southern Biotech, Birmingham, AL) at 30 mg/ml in pH 4.5
acetate were immobilized on the surface of ﬂow cells one and two
using amine coupling. Non-speciﬁcally associated antibody was
removed with three 5 ml injections of glycine-HCl, pH 1.5 at
100 ml/min. w1500 response units of BC3 or BC3-C2 diluted to
10 mg/ml in running buffer (HEPES buffered saline containing
3 mM EDTA and 0.05% Tween, HBS-EP, Biacore BR-1006-69) was
captured from a 25 ml injection at a ﬂow rate of 5 ml/min.
Increasing concentrations of the neoepitope peptide were injec-
ted for 5 min at a ﬂow of 30 ml/min followed by a 10 min disso-
ciation phase. The surfaces were regenerated following each
dissociation phase with two 15 ml injections of glycineeHCl, pH
1.5 at a ﬂow rate of 50 ml/min. Kinetic constants were determined
using the T100 Evaluation software. Speciﬁcity for the neoepitope
was tested by injections of 100 nM spanning peptide under the
described assay conditions.Western blot analysis
15 mg of native human aggrecan  ADAMTS-4 (overnight
digestion) was loaded on a NuPAGE 4e12% BiseTris gel and sepa-
rated by SDS-PAGE under reducing conditions. The proteins were
transferred to PVDF membranes followed by incubation with BC3
supernatant (1:250 dilution) or BC3-C2 (1:1000 dilution) overnight
at 4C. After washing, the membranes were incubated with horse
radish peroxidase (HRP)-conjugated goat anti-mouse IgG (Jackson
Immunoresearch) at a dilution of 1:7500 for 1 h at room temper-
ature. The supersignal west pico chemiluminescent substrate kit
(Thermo Scientiﬁc) was used for signal development.
HAC explant assay
Articular cartilage was obtained from patients at the time of
joint replacement surgery, with informed consent. Healthy-looking
cartilage was shaved off the femoral condyle and tibial plateau,
minced into approximately 1e2 mm3 pieces and rinsed for 2 h in
incubation medium [serum free DMEM:F12 (3:1) supplemented
with ITS, 20 mM glutamate, 10 mM HEPES, 1 uM zinc acetate, and
0.1 antibiotic/antimycotic] prior to use. 100 mg of rinsed cartilage
was then randomly distributed into 2 ml sterile microcentrifuge
tubes containing 1 ml of incubation medium. 10 ul of the test
compounds (compound B or CP-66968527,28) was added from
a 100 DMSO stock solution. The incubations were conducted at
37C while shaking at w150 rpm for 48 h and conditioned media
were collected and analyzed by the BC3-C2 ELISA. One-way ANOVA
model was applied to ﬁt the data, considering each treatment
condition as a separate group. The data were transformed by
logarithm to satisfy model assumptions. The model residuals were
checked for equal variance across groups. ShapiroeWilk test was
applied and showed that the normal distribution assumption is
satisﬁed. Dunnett’s t-test was applied to compare each treatment
with control. Data analysis was carried out using statistical soft-
ware JMP (SAS Institute, NC).
BC3-C2 sandwich ELISA
The BC3-C2 antibody was used as a capture antibody and HRP-
conjugated a-HABR antibody was used as the detection antibody.
The BC3-C2 antibodywas immobilized onwhite high binding ELISA
plates (Nunc) overnight at 4C at a concentration of 1 mg/ml.
Following blocking in 1 PBS, 3% BSA and 0.05% Tween, samples
were added to the plate and ARGS containing fragments were
captured, and then detected using the HRPeHABR antibody
(1:8000 dilution). The ELISA signal was measured using the
Supersignal ELISA Femto Maximum Sensitivity Substrate (Pierce)
and read on a Victor luminometer. The amount of aggrecan frag-
ments present in the sample was determined based on a standard
curve generated with ADAMTS-4 digested recombinant G1-IGD-G2
of aggrecan (that gets cleaved into G1—NITEGE and ARGS—G2
fragments by ADAMTS-4) (catalog number 1220-PG-025, R&D
Systems, Minneapolis, MN). Statistical analysis was performed
using Dunnett’s test.
Urine creatinine assay
Creatinine levels in human urine samples were determined
using an ELISA kit purchased fromR&D Systems (Minneapolis, MN).
Results
Cleavage of aggrecan within the IGD occurs at the E373eA374
bond resulting in the generation of the NITEGE373 and 374ARGS
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Fig. 1. Schematic structure of aggrecan showing the globular domains (G1 and G2), HABR motifs in the G1 and G2 domains, and the presence of sulfated sugar substitutions.
(adapted from29,30).
C.A. Swearingen et al. / Osteoarthritis and Cartilage 18 (2010) 1150e1158 1153neoepitopes11. The G1 and G2 globular domains of aggrecan share
structural similarities in that they both contain two copies of
a HABR motif (also known as proteoglycan tandem repeat or PTR)
(Fig. 1)29,30. We took advantage of the HABR motifs in the G2
domain and developed a sandwich ELISA using the a-HABR anti-
body that recognizes the G2 (and G1) domains of aggrecan as
capture antibody and the BC3 antibody (that recognizes the ARGS
neoepitope exposed upon aggrecanase cleavage within the IGD) as
detection antibody (manuscript submitted). This ELISA can be used
to measure aggrecan fragments in deglycosylated human synovial
ﬂuid samples. However, the BC3 antibody was not suitable for
measuring ARGS containing fragments in the native state (without
deglycosylation) or in serum or urine samples (data not shown)
because of the low afﬁnity (high off rate) of the antibody (Fig. 2)
combined with the reported lower levels of aggrecan fragments in
serum and urine compared to synovial ﬂuid15.Optimization of the BC3 antibody to improve its binding afﬁnity to
the ARGS/ARGN neoepitope
In an effort to develop a sensitive assay to measure ARGS frag-
ments in the native state (without deglycosylation) in human
biological ﬂuids that are more clinically accessible (serum and
urine), we sought to improve the afﬁnity of the BC3 antibody via in
vitro directed evolution. The BC3 VH and VL genes were obtained
from the hybridoma cell line and mutations were introduced into
the CDRs to identify variants with improved binding. The optimized01-
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Fig. 2. Biacore analysis of the BC3 monoclonal antibody showing the high off rate of
the antibody. NITEGEARGS¼ spanning peptide showing no reactivity.antibody clone BC3-C2 contains mutations in multiple CDRs that
resulted in a 4-log improvement in binding afﬁnity for the ARGS
peptide compared to that of the BC3 antibody [Fig. 3(a)], while
maintaining its ability to cross-react with both ARGS (human) and
ARGN (rat) neoepitopes [Fig. 3(b)]. The BC3-C2 antibody showed
greatly improved off rates compared to the BC3 antibody [Fig. 3(c)].
Western blot analysis of ADAMTS-4 digested human aggrecan
demonstrated that the BC3-C2 antibody recognizes fragments of
the same size as the BC3 antibody in the digested sample (new
[Fig. 3(d)]).
Development of the BC3-C2 ELISA
To demonstrate the utility of the BC3-C2 antibody, we devel-
oped a sandwich ELISA using native human aggrecan that was
digested with ADAMTS-4 to generate the ARGS neoepitope. ARGS
containing fragments were captured with the BC3-C2 antibody and
the captured fragments were then detected with a HRP-conjugated
a-HABR antibody. We observed a speciﬁc signal with ADAMTS-4
digested, but not undigested aggrecan (Fig. 4) demonstrating the
speciﬁcity of the BC3-C2 antibody. This also indicates the ability of
this assay to detect aggrecanase-cleaved aggrecan fragments with
no need for deglycosylation. In contrast, the BC3 antibody was not
able to capture ADAMTS-4 cleaved aggrecan in this sandwich ELISA
format (Fig. 4).
Inhibition of ARGS fragment release by aggrecanase inhibitors in
HAC explants in culture
To determine the speciﬁcity of the signal detected by the BC3-C2
ELISA, we utilized a HAC explant culture system using tissue
obtained from patients undergoing knee replacement surgery.
Cartilage explant cultures were set up as described in Materials and
methods and were incubated at 37C and the conditioned media
were collected at 48 h for analysis. The ELISA assay was capable of
detecting the basal levels of ARGS containing fragments released
into the medium by the diseased cartilage explants without the
need for induction by IL-1 and oncostatin M (Fig. 5). Treatment of
these cultures with either a broad-spectrum inhibitor of MMPs/
aggrecanases (CP-669685) or a selective aggrecanase inhibitor
(compound B) that is >1000-fold more selective for inhibiting
aggrecanases compared to a number of MMPs, resulted in a dose-
dependent inhibition of the signal conﬁrming the involvement of
aggrecanase activity in the generation of these fragments and the
speciﬁcity of the signal detected. CP-669685 is 10-fold more potent
in inhibiting aggrecanases (compared to compound B) and this
increased potency translated to greater inhibitory activity of this
compound at low doses in the cartilage explant assay as well
(Fig. 5).
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Fig. 3. (a) Afﬁnity of the BC3 and BC3-C2 single-chain antibodies for binding to the ARGS neoepitope. The mean ﬂuorescent intensity (MFI) of the antigen-binding channel was
measured after incubation with increasing concentrations of ARGS-Bt peptide antigen. Minimal antigen binding is observed with BC3 at the highest antigen concentration (3.2 mM).
(b) Afﬁnity of the BC3-C2 single-chain antibody for binding to the rat (ARGN) and human (ARGS) neoepitopes. Quantitative equilibrium binding was determined using ﬂow
cytometry. The Ag-binding MFI was normalized and ﬁt to a nonlinear least-squares regression to calculate the equilibrium afﬁnity constant. Bt: biotinylated peptide. (c) Biacore data
comparing the afﬁnities of the BC3 and BC3-C2 IgG antibodies. BC3 and BC3-C2 IgG were immobilized and antigen-binding responses measured by surface plasmon resonance using
Biacore instrumentation. Representative data from separate experiments were combined to highlight the change in dissociation rate of BC3-C2 after antibody optimization. (d)
Western blot analysis of human aggrecan digested with or without ADAMTS-4 and detected with the BC3 or BC3-C2 antibody.
C.A. Swearingen et al. / Osteoarthritis and Cartilage 18 (2010) 1150e11581154Detection of ARGS containing fragments in human synovial ﬂuid
To test the potential clinical utility of this assay, we tested
human synovial ﬂuid samples obtained from patients undergoing
knee replacement surgery using this ELISA assay without any
deglycosylation. As shown in Fig. 6(a), we could readily measure
these fragments in the synovial ﬂuid of these patients and the
signal was completely eliminated in the presence of a 22-mer
competing peptide that contains the ARGS neoepitope sequence
(ARGSVILTVKPIFEVSPSPLKG), but not by a 43-mer spanning
peptide, demonstrating the speciﬁcity of the antibody.Fig. 4. Comparison of the BC3 and BC3-C2 antibodies for capturing human aggrecan in
the sandwich ELISA. Varying amounts of native human aggrecan  ADAMTS-4
digestion were analyzed by sandwich ELISA using the BC3 or BC3-C2 antibody as
capture antibody. NHA: native human aggrecan; TS-4: ADAMTS-4/aggrecanase-1.Detection of ARGS containing fragments in human serum and urine
Since the synovial ﬂuid samples are not readily accessible in the
clinic, we tested whether the BC3-C2 ELISA is capable of detecting
ARGS containing fragments in systemic circulation and in urine, to
understand the broader potential for using this assay in more
clinically accessible ﬂuids. The parental BC3 antibody, in particular,
was not useful for measuring aggrecanase-cleaved aggrecan neo-
epitopes in serum and urine in an ELISA format (data not shown),
likely due to the low afﬁnity of the antibody, the lower levels of
aggrecan fragments in serum and urine compared to synovial
ﬂuid15, and possible interference from these biological matrices.
Interestingly, wewere able to detect a speciﬁc signal both in human
plasma and urine with the BC3-C2 ELISA [Fig. 6(b)]. The speciﬁcity
of detection was demonstrated by competition with the 22-mer
peptide containing the ARGS neoepitope and lack of competitionwith a 43-mer spanning peptide that does not have the neoepitope
exposed (VQT.NITEGEARGS.LKG).
To further demonstrate the utility of this ELISA for detecting
aggrecanase-cleaved aggrecan fragments in the clinical situation,
we obtained serum and urine samples from a methods study
conducted at Lilly with individuals that were identiﬁed as having
Fig. 6. (a) BC3-C2 ELISA with human synovial ﬂuid samples obtained from joint
replacement patients (numbered 1e8). The samples were treated with hyaluronidase
and tested in duplicate at a ﬁnal concentration of 0.25%. Varying levels of ARGS con-
taining fragments were detected in the synovial ﬂuid from patients. Addition of a 22-
mer competing peptide (1 uM) resulted in a complete loss of signal, whereas addition
of a 43-mer spanning peptide (1 uM) had no effect, demonstrating the speciﬁcity of
neoepitope detection. (b) Detection of ARGS fragments in human plasma and urine.
Human plasma or urine was analyzed (in duplicate) by the BC3-C2 ELISA in the
presence or absence of a 22-mer competing peptide or a non-competing 43-mer
spanning peptide. Error bars represent the standard deviation of the mean.
Fig. 5. Detection of ARGS containing fragments in HAC explant cultures. HAC obtained
from a patient undergoing joint replacement surgery was cultured as described in the
Materials and methods section and incubated in the presence or absence of a broad-
spectrum aggrecanase/MMP inhibitor (CP-669685) or a selective aggrecanase inhibitor
(compound B). After 48 h of incubation, the culture medium was collected and
analyzed for ARGS fragment levels using the BC3-C2 ELISA. Data shown are the mean
ARGS fragment levels observed in an experiment done with n¼ 5 per treatment group
for the compound treatments and n¼ 10 for the DMSO control group. Error bars
represent the 95% conﬁdence intervals. Statistical signiﬁcance in comparison to the
DMSO control group is indicated by an asterisk (p< 0.05) and the p-values (deter-
mined using Dunnett’s test) are shown in the table.
C.A. Swearingen et al. / Osteoarthritis and Cartilage 18 (2010) 1150e1158 1155no, mild or moderate OA (n¼ 14 per group). Categorization into
groups was based on both clinical exams and radiographic analysis
of the knee, hip and spine. Serum and urine samples were collected
at baseline (visit 1) and at 2-week (visit 2) and 4-week (visit 3)
follow-up. The ELISA clearly showed the presence of ARGS con-
taining fragments in serum in all three groups at all time points
tested (Fig. 7). Interestingly, we noticed a trend toward an increase
in biomarker levels going from no OA to mild and moderate OA
samples. In addition, at all three time points, the moderate OA
patients had a signiﬁcantly higher level of the neoepitope
compared to individuals with no OA. We were also able to detect
ARGS containing fragments in urine in all three groups at all time
points tested, although there was not a signiﬁcant difference in
levels between the groups (Fig. 8).
Discussion
Aggrecanase-mediated degradation of aggrecan is a hallmark
feature of OA. Since the progression of OA is a very slow process
that happens over decades, it is imperative to have a sensitive
biomarker assay to facilitate patient selection and dose setting in
the clinic and possibly provide an early indication of drug activity in
clinical trials. In addition, biomarkers may offer the ability to
identify patients with cartilage damage early in the disease process
and could therefore facilitate early therapeutic intervention. There
is an example of an ELISA assay (KS/OA-1 ELISA) to speciﬁcally
detect aggrecanase-cleaved fragments of aggrecan in the synovial
ﬂuid14,17. However, this assay is unable to detect the fragments in
systemic circulation or in urine (ﬂuids that are readily accessible in
the clinic). It is likely that the sensitivity of this assay is not sufﬁ-
cient to measure the low levels of aggrecan core protein (or frag-
ments thereof) in serum and urine compared to the synovial ﬂuid15.
There are no assays currently available (other than western blot
analysis16) to measure systemic levels of aggrecanase-cleaved
aggrecan fragments. To overcome this limitation, we utilized an
antibody optimization technique to develop an a-ARGS antibody
(BC3-C2) that has a 10,000-fold improvement in afﬁnity for theneoepitope (compared to the parental BC3 antibody) with no
appreciable binding to an uncleaved (ﬂanking) peptide comprising
the aggrecanase cleavage site sequence in aggrecan. Using the
optimized antibody, we have developed a sensitive sandwich ELISA
and have demonstrated the utility of this assay to measure aggre-
can degradationproducts in human synovial ﬂuid, serum and urine.
The BC3-C2 antibody is capable of capturing both ARGS (human)
and ARGN (rat) epitopes equally well. Since this epitope is fairlywell
conserved among various mammalian species (human, rat, cattle,
sheep, dog, rabbit, and horse)31 this assay has the potential to
measure aggrecanase-cleaved aggrecan fragments in the biological
ﬂuids from multiple species. In future studies, it would be worth
testing the utility of this assay to measure biomarker levels in these
species and determine how the levels vary with age and with
progression of OA in response to surgical destabilization of the joint
(eg. anterior cruciate ligament transection in dogs, rabbits, rats, etc.)
or other insults. This assay would also be useful to screen for aggre-
canase inhibitory molecules in vitro and in animal models of OA.
The data from this study indicate that large aggrecanase-cleaved
ARGS containing aggrecan fragments that also contain the HABR
reactive G2 domain are indeed present in human serum and urine.
It is not known whether the fragments that we measure in serum
and urine still contain any sulfated sugar chains. In addition, the
identity of the C-terminal ends of these fragments (past the HABR
Fig. 7. Analysis of human serum samples in the BC3-C2 ELISA. Serum samples obtained in a methods study from patients with no, mild or moderate OA at three visits were analyzed
for ARGS containing fragment levels (ﬁnal serum concentration: 2%). Statistical analysis was performed using Dunnett’s test. The asterisks denote a statistically signiﬁcant difference
in serum biomarker levels in the moderate OA group compared to the no OA group. All p-values indicated are in comparison to the no OA group.
C.A. Swearingen et al. / Osteoarthritis and Cartilage 18 (2010) 1150e11581156reactive G2 domain) cannot be elucidated from the results of this
study. It is likely that the fragments that are detected in this assay
contain varying C-terminal ends corresponding to the four other
aggrecanase cleavage sites in the CS-rich CS-2 domain of aggrecanFig. 8. Analysis of the human urine samples in the BC3-C2 ELISA. Urine samples obtained
analyzed for ARGS containing fragment levels (ﬁnal urine concentration: 6.25%). The data
comparison to the no OA group are indicated.or they may contain an intact C-terminus of aggrecan9,10. However,
small fragments of aggrecanase-cleaved aggrecan that contain the
ARGS sequence but lack the G2 domain (because of further
proteolytic processing) will not be detected by this assay.in a methods study from patients with no, mild or moderate OA at three visits were
were normalized to creatinine and expressed as pg ARGS/mg creatinine. p-values in
C.A. Swearingen et al. / Osteoarthritis and Cartilage 18 (2010) 1150e1158 1157Using serum and urine samples from a small set of patients, we
have demonstrated the utility of this assay to measure ARGS frag-
ments in these two biological matrices. In serum, the biomarker
levels showed an increasing trend going from no OA to mild and
moderate OA at all three time points tested. The increase in
biomarker levels in the moderate OA group was statistically
signiﬁcant in comparison to the no OA group. These data suggest
the potential clinical utility of the serum assay to determine the
joint disease status of patients, although the group sizes in this
study were small and there is a need to test additional patient
samples to determine the diagnostic value of this biomarker. In
urine, our results showed consistent levels of ARGS fragments over
time. These levels correlate well with the values obtained using
a different approach (immunoafﬁnity capture/mass spectrometry
assay to capture and quantify ARGS containing fragments) (data not
shown). However, there was no difference in the urinary levels of
the biomarker between the three groups of patients at any of the
time points tested.
We need to test additional clinical samples to determine diurnal
variation (if any) in the levels of aggrecan fragments in serum and
urine, patient to patient variability, correlation between biomarker
levels and disease status in patients with varying degrees of OA,
inﬂammatory arthritis, and other joint arthropathies, to better
understand the utility of this assay to stratify patients based on
etiology and/or severity of cartilage damage. In addition, testing of
matched synovial ﬂuid, serum and urine from well annotated
patient samples would be needed to determine the correlation
between fragment levels in these ﬂuids and joint disease status.
Further, there is a need to test longitudinal samples collected over
a period of time to determine how the marker varies with time
after injury or with wear and tear of the joint.
To summarize, we have developed a novel ELISA and have
demonstrated for the ﬁrst time, the ability to measure speciﬁc
aggrecanase-cleaved ARGS containing fragments of aggrecan in
human serum and urine using an ELISA-based format. The ability to
run this assay in a 96-well plate format makes it an ideal assay for
testing human samples with increased throughput. It has the
potential to serve as amechanistic drug activity biomarker assay for
the clinical testing of aggrecanase inhibitors and other disease
modifying osteoarthritic drugs that directly or indirectly impact
aggrecanase activity.Author contributions
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